Soleno Therapeutics, Inc. Common Stock (SLNO) Financials
Key financial figures for Soleno Therapeutics, Inc. Common Stock (Q1 2026).
Soleno Therapeutics Inc. reported revenue of $94.6 million for Q1 FY2026. Net income was $31.4 million, or $0.59 per share. Operating margin came to 33.57%. Free cash flow for the period was $25.9 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Soleno Therapeutics Inc. are on the SentiSense financials page.
- Revenue
- $95M
- Net Income
- $31M
- EPS
- $0.60
- Total Assets
- $608M
- Operating Cash Flow
- $26M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q1 FY2026 | $95M | $31M | $0.59 | 33.57% | $26M |
| Q4 FY2025 | $92M | $43M | $0.80 | 44.08% | $49M |
| Q3 FY2025 | $66M | $26M | $0.47 | 33.48% | $44M |
| Q2 FY2025 | $33M | -$5M | -$0.09 | -19.98% | -$13M |
| Q1 FY2025 | $0 | -$44M | -$0.95 | -$33M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $190M | $21M | $0.39 | 7.85% | $47M |
| FY2024 | $0 | -$176M | -$4.38 | -$69M | |
| FY2023 | $0 | -$39M | -$2.36 | -$25M |
Frequently asked questions
What was Soleno Therapeutics Inc.'s revenue last quarter?
Soleno Therapeutics Inc. reported revenue of $94.6 million for Q1 FY2026.
Is Soleno Therapeutics Inc. profitable?
Yes. Soleno Therapeutics Inc. reported net income of $31.4 million for Q1 FY2026, a net margin of 33.17% on revenue.
How has Soleno Therapeutics Inc.'s margin trended?
Operating margin was 33.57% in Q1 FY2026. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Soleno Therapeutics Inc. generate?
Soleno Therapeutics Inc. generated free cash flow of $25.9 million in Q1 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Soleno Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.